AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7399797
Drug: Topical extract
RxNorm normalized name: GLYCERIN 13.226 g in 100 mL TOPICAL EXTRACT [WELLAGE 4D Gold Essence]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical extract of Peganum harmala
Trial: 23415311
Drug: Lurasidone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 160 mg
Trial: 24385309
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 600 mg
Trial: 11754119
Drug: Nimesulide drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide drop formulation (50 mg x ml(‐1), Medley S/A Indústria Farmacêutica, Brazil)
Trial: 11754119
Drug: Standard nimesulide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nimesulide drop formulation (Nisulid, 50 mg x ml(‐1), Astra Médica, Brazil)
Trial: 8033369
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (n = 38)
Trial: 792665
Drug: Encephabol (pyritinol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encephabol (pyritinol, pyrithioxine) administered orally, parenterally, and combined
Trial: 20952100
Drug: Antithrombin treatment
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin treatment (unfractionated heparin, low-molecular-weight heparin, or bivalirudin)
Trial: 10671927
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antihypertensive medication
Trial: 8140382
Drug: Topical vasoconstrictor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vasoconstrictor pre-treatment
Trial: 8140382
Drug: No vasoconstrictor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vasoconstrictor pre-treatment (control)
Trial: 4030197
Drug: PPA 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 37.5 mg (therapeutic dose)
Trial: 25073857
Drug: Insulin Sensitization
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Sensitization (IS)
Trial: 25073857
Drug: Insulin Provision
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Provision (IP)
Trial: 20373130
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration before transfer to cathlab (group EA)
Trial: 20373130
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration during PPCI (group LA)
Trial: 20373130
Drug: Selective abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective abciximab administration during PPCI (group SA)
Trial: 18508946
Drug: Tonsillectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillectomy plus steroid pulse therapy (group C)
Trial: 18508946
Drug: Steroid pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid pulse monotherapy (group M)
Trial: 31841078
Drug: Lumbar Stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar Stabilization Treatment (LST)
Trial: 31841078
Drug: Cognitive Functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Functional Treatment (CFT)
Trial: 28317885
Drug: Magnesium-aluminium antacid
RxNorm normalized name: Magnesium aluminium silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-aluminium antacid gel
Trial: 24791346
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% lotion applied twice with a one week interval
Trial: 24791346
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral ivermectin
Trial: 24791346
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ivermectin
Trial: 16449486
Drug: Nalmefene 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 25 mg/day
Trial: 16449486
Drug: Nalmefene 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 50 mg/day
Trial: 16449486
Drug: Nalmefene 100
RxNorm normalized name: nalmefene 100 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 100 mg/day
Trial: 15290730
Drug: LEF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEF (10 mg/day, no loading dose) + MTX
Trial: 15290730
Drug: PLA +
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PLA + MTX switched to LEF (10 mg/day, no loading dose)
Trial: 15290730
Drug: LEF (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEF (no loading dose)
Trial: 11273907
Drug: Insulin-enhanced cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-enhanced cardioplegia (Humulin R 10 IU/L, Insulin group, n = 243)
Trial: 11273907
Drug: Insulin-enhanced cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-enhanced cardioplegia
Trial: 11049005
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac (75 mg)
Trial: 31433134
Drug: EndoUltra: 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoUltra: 2.5 ml of 7% MA for 30 s, followed by EndoUltra activation for 30 s
Trial: 31433134
Drug: EndoSafe: EndoSafe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoSafe: EndoSafe irrigation system for 1 minute using 5 ml of 7% MA
Trial: 31433134
Drug: Side‐vented needle:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side‐vented needle: 30 gauge needle irrigation for 1 min using 5 ml of 7% MA
Trial: 25450818
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day, n=46)
Trial: 25450818
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg/day, n=42)
Trial: 25450818
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Pioglitazone and Metformin
Trial: 18281113
Drug: Magnesium orotate
RxNorm normalized name: Magnesium orotate
DrugBank: Magnesium orotate (DB13786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n=40)
Trial: 16948809
Drug: RWJ-351647 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-351647 (1, 2, and 5 mg doses)
Trial: 16948809
Drug: RWJ-351647 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-351647 (5 mg)
Trial: 11380515
Drug: NG-Monomethyl-L-arginine (L-NMMA)
RxNorm normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-Monomethyl-L-arginine (L-NMMA)
Trial: 24929883
Drug: Halobetasol 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol 0.05% ointment
Trial: 18566839
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide therapy
Trial: 18566839
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous dexamethasone and oral cyclophosphamide therapy
Trial: 16783294
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing Lactobacillus acidofilus
Trial: 16783294
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing Lactobacillus acidofilus + oral Lactobacillus paracasei subsp paracasei F19
Trial: 14557449
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose soy isoflavones (1.0 g soy extracts, approximately 80 mg isoflavones)
Trial: 14557449
Drug: Mid-dose soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose soy isoflavones (0.5 g starch, 0.5 g soy extracts, approximately 40 mg isoflavones)
Trial: 14557449
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g starch)
Trial: 8871338
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no self-hypnotic relaxation)
Trial: 25920599
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (placebo)
Trial: 6338794
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid therapy (combined results)
Trial: 27009620
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (n=833)
Trial: 27009620
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (n=821)
Trial: 27009620
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockade (n=830)
Trial: 27009620
Drug: Evening variability
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening variability independent of the mean (before treatment)
Trial: 27009620
Drug: Home BPV
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home BPV captured after monotherapy
Trial: 20142543
Drug: Angiotensin-receptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-receptor blocker (losartan potassium) or angiotensin-converting enzyme inhibitor (enalapril maleate)
Trial: 17324145
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once daily for 12 weeks, followed by placebo for 2 weeks and then metoprolol succinate 95 mg once daily for 12 weeks
Trial: 17324145
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 95 mg for 12 weeks, placebo for 2 weeks and then nebivolol 5 mg for 12 weeks
Trial: 12066489
Drug: Southern Implants
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern Implants
Trial: 12066489
Drug: All implant
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implant systems
Trial: 1718158
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (encainide/flecainide)
Trial: 6224684
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily
Trial: 6224684
Drug: Cotrimoxazole 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole 160/800 mg twice daily
Trial: 24832559
Drug: Film-coated ethionamide
RxNorm normalized name: ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated ethionamide tablets (250 mg)
Trial: 24832559
Drug: Sugar-coated ethionamide
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated ethionamide tablets (250 mg)
Trial: 17894303
Drug: Weight-based ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-based ribavirin (RBV) 800-1400 mg/day
Trial: 17894303
Drug: Flat-dose ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flat-dose ribavirin (RBV) 800 mg/day
Trial: 17894303
Drug: Flat-dose RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flat-dose RBV in genotype 1 patients
Trial: 17894303
Drug: Flat-dose RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flat-dose RBV in genotype 1 patients with high baseline viral load
Trial: 17894303
Drug: Flat-dose RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flat-dose RBV in genotype 2/3 patients
Trial: 9227164
Drug: etidronate +
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etidronate + sodium fluoride (NaF) 25 mg twice daily
Trial: 7958497
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ANG II infusion
Trial: 7958497
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ANG II infusion
Trial: 30977767
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum sodium levels (≥141 mmol/L)
Trial: 29033294
Drug: Acetaminophen 4,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4,000 mg/day + Diclofenac 150 mg/day
Trial: 27737649
Drug: Benzodiazepine tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzodiazepine tapering
Trial: 18249478
Drug: IFN-alpha as
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha as an adjuvant of HBV vaccine
Trial: 18249478
Drug: Control (HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (HBV vaccine without IFN-alpha)
Trial: 16754246
Drug: Semantic word
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semantic word lists (e.g., bed, rest, wake)
Trial: 16754246
Drug: Phonological word
RxNorm normalized name: OTOLOGICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonological word lists (e.g., pole, bowl, hole)
Trial: 6941637
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to a cold room (‐10 degrees C) and inhalation of very cold air (‐35 degrees C)
Trial: 6941637
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to 10 and 0 degrees C environmental temperature and inhalation of moderately cold air (‐10 degrees C)
Trial: 28032303
Drug: Hydrocortisone (HCT)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HCT) administration
Trial: 26338885
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol supplements of 10 μg/d for 3 mo
Trial: 26338885
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol supplements of 25 μg/d for 3 mo
Trial: 26338885
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol supplements of 50 μg/d for 3 mo
Trial: 21169285
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PET and VDT
Trial: 8953681
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d. for 6 days
Trial: 1789034
Drug: Lyophilized acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized acellular staphylococcal vaccine
Trial: 23864540
Drug: Oral thiamine
RxNorm normalized name: thiamine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thiamine hydrochloride 100 mg for 5 days
Trial: 18244953
Drug: TPI ASM8
RxNorm normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPI ASM8 (1,500 microg, inhaled by nebulizer, once daily for 4 days)
Trial: 15697326
Drug: Zolmitriptan 5mg
RxNorm normalized name: ZOLMITRIPTAN 5MG TAB PKG 3
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5mg nasal spray
Trial: 10932687
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 propofol
Trial: 10932687
Drug: 2.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg.kg‐1 propofol
Trial: 10932687
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose propofol (1.5 mg.kg‐1)
Trial: 10932687
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose propofol (2.5 mg.kg‐1)
Trial: 1768565
Drug: Atenolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (1 x 100 mg day‐1) for 6 weeks
Trial: 1768565
Drug: Captopril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (1 x 100 mg day‐1) for 6 weeks
Trial: 6817776
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 20 mg q.d.s.
Trial: 6817776
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg b.d.
Trial: 31927027
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 52 mg IUS
Trial: 23904883
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) + Metformin
Trial: 23019938
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) alone
Trial: 21338805
Drug: High-milk, early-weaned:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-milk, early-weaned: fed 12 L/d of milk and weaned at 47 d of age
Trial: 21338805
Drug: Low-milk, early-weaned:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-milk, early-weaned: fed 6 L/d of milk and weaned at 47 d of age
Trial: 21338805
Drug: High-milk, later-weaned:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-milk, later-weaned: fed 12 L/d of milk and weaned at 89 d of age
Trial: 17418321
Drug: Hygiene promotion
RxNorm normalized name: PROMOTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygiene promotion (medicine provided and hygiene promotion activity)
Trial: 17418321
Drug: Treatment (medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (medicine provided, no hygiene promotion activity)
Trial: 17418321
Drug: Seasonality (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonality (no medicine, no hygiene promotion activity)
Trial: 16802774
Drug: Montelukast, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 10 mg daily
Trial: 8500867
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg indomethacin for 5 days
Trial: 30789808
Drug: Resveratrol 600
RxNorm normalized name: RESVERATROL 600 mg / NICOTINAMIDE MONONUCLEOTIDE 500 mg / WHITE PEPPER 50 mg ORAL CAPSULE [Ascuoli]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 600 mg daily for 12 weeks
Trial: 27091274
Drug: Heel suspension
RxNorm normalized name: benzyl alcohol / lidocaine hydrochloride Topical Spray [Biochemistry Heel No Pain]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heel suspension device boot
Trial: 24689967
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (4 g daily for 6 weeks)
Trial: 24689967
Drug: Placebo (identical-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-looking capsules for 6 weeks)
Trial: 20156150
Drug: Galantamine (8-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (8-32 mg for IR tablets; 8-24 mg for ER capsules)
Trial: 20156150
Drug: Galantamine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine co-administered with ketoconazole
Trial: 20156150
Drug: Galantamine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine co-administered with paroxetine
Trial: 18294323
Drug: Ifosfamide 9
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide 9 g m(‐2) given by a 3 h infusion
Trial: 18294323
Drug: Ifosfamide 9
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide 9 g m(‐2) given by a 72 h infusion
Trial: 14516798
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (Group 3)
Trial: 14516798
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tear substitute (ATS) (Group 1)
Trial: 11368654
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of OSA-substituted starch